A variety of organisms, such as bacteria, fungi, and plants, produce secondary metabolites,
also known as natural products. Natural products have been a prolific source and an …

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

Malaria causes high levels of morbidity and mortality in human beings worldwide. According
to the World Health Organization (WHO), about half a million people die of this disease each …

Malaria vaccine development has rapidly advanced in the past decade. The very first phase
3 clinical trial of the RTS, S vaccine was completed with over 15,000 African infants and …

Background GMZ2 is a recombinant malaria vaccine inducing immune responses against
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …

Background BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based
on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to …

Background Two pre-erythrocytic vaccines (R21/Matrix-M and RTS, S/AS01) are now
approved for Plasmodium falciparum malaria. However, neither induces blood-stage …